Trial Profile
Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DAPHNIS
- 27 Aug 2018 Planned End Date changed from 31 Mar 2018 to 31 Aug 2018.
- 03 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Mar 2018 Planned End Date changed from 1 Mar 2017 to 31 Mar 2018.